1 s e~~~~~~~ Endocrine treatment of prostatic cancer Within four years of Huggins & Hodges (1941) describing their rationale for the endocrine treatment of prostatic cancer, it was realized that not all patients responded (approximately 70-80%) and that of those that did, over half would relapse within two to three years (Huggins & Scott 1945) . The five-year survival for those with metastatic disease is only 25%, with no more than 10% surviving 10 years (Walsh 1975 , Reiner et al. 1979 . Despite these depressing statistics, there have been few advances in the management of this disease over the past 40 years. Orchidectomy or low-dose stilboestrol are still the standard therapies offered by the majority of British urologists to those patients with advanced disease. Since the disease at this stage cannot be cured by surgery, it could be argued that a patient with metastatic prostatic cancer should not be managed solely by a urological surgeon. In the United States, the lifetime probability of developing prostatic cancer is 5.2% and 9.6% in white and black males respectively (Mettlin 1983) . This high incidence is also reflected in the United Kingdom, where between 6000 and 8000 new cases of prostatic cancer will be diagnosed in 1985. The majority of these will, at the time of presentation, have disease which is locally advanced or have metastasized to bone or lymph nodes.
In order to bring together the expertise of urologists, endocrinologists, biochemists and other scientists to try and link basic science with clinical problems, the British Prostate Group was founded in 1975. Unfortunately, as membership increased the productivity decreased, with an increasing separation between scientists with their arguments over technique and methodology, and clinicians frustrated with lack of progress, and often an inability (with apologies to those who did), to understand, for example, Kd B-max or a Scatchard Plot. This separation of basic scientists and clinicians has been compounded by the failure to develop academic units in urology.
There have been very few nationally organized collaborative studies on the treatment of prostatic cancer in the United Kingdom. One such study about to commence is being organized by the Medical Research Council Working Party on Urological Cancer. Patients with advanced local disease or asymptomatic metastatic disease will be allocated to one of two treatment groups-either immediate orchidectomy or orchiict _00 symptoms ensue. Yet orchidectomy has never been shown convincingly to increase patient survival. On the other hand, in one of the later VACURG studies (Blackard 1975) , which compared diethylstilboestrol at 0.2 mg, 1 mg and 5 mg daily, improved survival and decreased progression rates were demonstrated with the two higher dose schedules; relapsing patients were switched to alternative therapy. Thus, this study, using a very low dose of diethylstilboestrol, actually compared early and delayed hormonal treatment, and as such delayed treatment seemed to be as effective as earlier treatment. It seems unlikely that the MRC study will produce much new information of value to the individual patient. Furthermore, it is likely that orchidectomy, as sole therapy for this disease, will be superseded by the use of combined endocrine therapy.
An early answer applicable to the individual patient might be obtained by determination of the steroid receptor status , Concolino et al. 1982 , Trachtenberg & Walsh 1982 . There have also been many refinements in techniques for receptor assays , Pontes et al. 1982 ) and a better understanding, particularly of tumour heterogeneity, at a cellular level (Isaacs 1982) . Our current concepts assume that receptor-rich tumour cells retain characteristics of normal cells, and will respond to the endocrine manipulation aimed at those receptors. In receptor-positive tumours, treatment could be withheld until symptoms ensue, and a prolonged response to therapy could be expected. To date only small numbers of patients have been studied, and the majority of these are in the United States, but a number of authors have shown a positive correlation between nuclear androgen receptor concentration and duration of response and survival (Trachtenburg & Walsh 1982 .
Studies on the mechanism of action of androgens in the prostate have clearly demonstrated the vital role of the initial conversion of testosterone to dihydrotestosterone under the influence of the enzyme 5-alpha reductase, and the binding of dihydrotestosterone to the cytoplasmic receptor which translocates to the nucleus. While orchidectomy and oestrogens cause a 90-95% reduction in serum testosterone levels, a much smaller effect is seen on the intraprostatic concentration of dihydrotestoterone, which is only reduced by approximately 50% (Geller et al. 1978) . A number i) 1985 The Royal Society of Medicine 0141-0768/85/100797-03/$02.00/0 of drugs which affect these various steps have been tried, and include antiandrogens, antioestrogens, prolactin inhibitors, and other agents which inhibit testosterone production. Cyproterone acetate is the most frequently used antiandrogen. It inhibits testosterone production, but not to the castrate range, and also blocks the formation of the dihydrotestosterone receptor complex within the prostatic cell. Flutamide, a non-steroidal antiandrogen, blocks the translocation of the dihydrotestosterone receptor complex into the nucleus. The effect on serum testosterone is to increase it into the high-normal range. There is no evidence to suggest that either of these two expensive agents is more beneficial than conventional therapy (Jacobi 1982 , Jacobo et al. 1976 ). Denis & Declercq (1980) reported no responses in 10 patients treated with an antioestrogen, tamoxifen. Prolactin exerts a synergistic action with testicular adrenal androgens, and accentuates the action of testosterone on the prostate (Farnsworth 1972) . However, no benefit has been reported in newly diagnosed patients treated with the prolactin inhibitor bromocriptine, in a dose of 7.5 mg daily (Coune & Smith 1975) . Progestogens inhibit testosterone production and medroxyprogesterone (Provera) has been included as one arm of an EORTC study, but results are not yet available. Blackard (1975) found no benefit when compared to 1 mg per day of diethylstilboestrol. Megestrol acetate has many theoretical advantages in that it decreases intraprostatic concentration of dihydrotestosterone, blocks 5-alpha reductase activity and decreases plasma testosterone without increasing concentrations of prolactin. However, testosterone suppression lasts for approximately two months, and then begins to rise. The combination of megestrol acetate and 'mini-dose', diethylstilboestrol, 0.1 mg daily has been shown by Geller et al. (1981) to be effective in the treatment of prostatic cancer, and produces prolonged testosterone suppression.
Ketoconazole, an imidazole derivative, in high dose produces both testicular and adrenal androgen ablation, and has been suggested by Trachtenberg & Pont (1984) to be a suitable agent for advanced prostatic cancer. However, it does not reduce testosterone to the castrate range in all men, and its eight-hour duration of action necessitates very strict compliance. The identification of luteinizing hormone-releasing hormone (LHRH) (Schally et al. 1971 ) has led to the development of many more potent analogues with a longer duration of action, and when reviewing the use of these analogues in the treatment of prostatic cancer it is important to know which drug, dose, route and frequency of administration was used, for all these affect the results. All LHRH analogues cause an initial stimulation of the LHRH receptor, resulting in an over-production of LH and thus testosterone. Provided a sufficient dose of the analogue is given, the pituitary receptors become blocked, and within 10-21 days testicular androgen production ceases. During this initial stimulatory period it has been estimated that 7% of patients treated will have suffered from a 'flare phenomenon', i.e. the disease undergoes a rapid period of progression, possibly under the influence of increased testosterone secretion. The extent of the flare varies from increased pain, the development of outflow obstruction, to the onset of spinal cord compression. There have also been reports that with all three agents in common use, i.e. buserelin, leuprolide and Zoladex, there is a failure to maintain castrate ranges of testosterone throughout a 24-hour period , Trachtenberg 1983 , Faur et al. 1983 . This phenomenon is related to the size and frequency of the dose given. The availability of a depot preparation of a LHRH analogue, Zoladex, administered subcutaneously every 28 days, is a significant advance, and this reliably suppresses testosterone throughout the 28-day period . LHRH analogues undoubtedly have some significant advantages over oestrogens with their cardiovascular complications, and over orchidectomy with its inherent psychological problems. However, since their action is to reduce testicular androgen production, it is unlikely that the longterm results of treatment will be any different from those seen with orchidectomy. The earlier results of treatment with all analogues is equal to those of conventional therapy (Smith 1984 ).
The treatments so far described ignore man's unique ability to produce, in the adrenals, androgens and large quantities of precursor steroids which are converted peripherally and into the prostate into active androgens, and may account for the failure of conventional therapy to both totally ablate androgen production and significantly reduce the intraprostatic concentrations of dihydrotestosterone. To neutralize the effect of these androgens, and to prevent the development of a flare reaction, Labrie and his colleagues have reported a series of studies using the LHRH analogue buserelin and an antiandrogen RU 23908 (anandron, or flutamide) (Labrie 1984 , Labrie et al. 1984a . Patients treated with this combination still showed a significant initial rise in LH and testosterone; however, the addition of the antiandrogen to the LHRH analogue not only prevented the occurrence of a flare phenomenon, but also resulted in an immediate response to treatment as measured by reduction in serum acid phosphatase. After a mean period of 14 months, 68% of their patients showed either a complete or partial response, using the National Prostate Can-Journal ofthe Royal Society ofMedicine Volume 78 October 1985 799 cer Project criteria (Slack 1984) . Confirmation of these results by other workers is eagerly awaited. We have had the opportunity of studying the role of adrenal androgens in a group of 21 patients with disease progression, whose testicular androgen production had been ablated either by prior orchidectomy or concomitant LHRH analogue therapy. Dramatic objective responses were seen in 30% of the patients studied, suggesting that some of these tumours retain some degree of androgen dependence (Williams et al. 1985) . Ketoconazole has advantages over aminoglutethimide, which also blocks adrenal androgen production, in that ketoconazole does not significantly impair cortisol production. The cortisol replacement therapy required with aminoglutethimide may account, in part, for some of the objective responses seen with this agent. Furthermore, side effects of aminoglutethimide, particularly lethargy and depression, limit the acceptability of this agent in elderly men.
The early results of combination therapy aimed at total androgen ablation, using orchidectomy or LHRH to block testicular androgen production in combination with an antiandrogen or drugs such as ketoconazole or dexamethasone to block adrenal androgen formation, appear to have significant advantages over single therapy. With the further development of receptor studies, and hopefully large clinical trials using combination therapy, some significant benefits beyond just palliation should at last be seen in the treatment of this disease.
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